Equity · Healthcare
KURA
NASDAQKura Oncology (KURA)
The line runs 9 USD on 3 August through 11 USD on 23 September, on a scale from 8 to 14. Days the market did not trade hold the previous close, flat.
- Market cap
- 978.6M USD
- Revenue, year to Dec 2025
- 67.5M USD
- EPS, diluted, year to Dec 2025
- −3.18 USD
- 52-week range
- 7.39 USD – 13.59 USD
- Avg volume
- 132.1K
as of Sep 23, 2026
Have Kura Oncology (KURA) insiders bought or sold shares recently?
In the 90 days to 1 Nov 2026, Kura Oncology insiders reported 11 open-market sales and 2 purchases (SEC Form 4).
Form 4, 90 days to 1 Nov 2026, newest reported trade 29 Sep 2026
Buys 2Sells 11Net bought $643KOther filings 1
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 29 Sep 2026 | FORD KATHLEENChief Operating Officer | Sell | 3,668 | 39K USD |
| 29 Sep 2026 | Leoni MollieChief Medical Officer | Sell | 28,802 | 310K USD |
| 29 Sep 2026 | Powl Brian T.Chief Commercial Officer | Sell | 15,430 | 166K USD |
| 28 Sep 2026 | Bair Teresa BrophyChief Legal Officer | Sell | 8,442 | 89K USD |
| 28 Sep 2026 | FORD KATHLEENChief Operating Officer | Sell | 6,906 | 72K USD |
| 28 Sep 2026 | Leoni MollieChief Medical Officer | Sell | 12,448 | 131K USD |
| 28 Sep 2026 | DOYLE THOMAS JAMESSVP, Finance & Accounting | Sell | 4,607 | 48K USD |
| 28 Sep 2026 | Powl Brian T.Chief Commercial Officer | Sell | 17,020 | 179K USD |
| 24 Sep 2026 | Burrows FrancisChief Scientific Officer | Sell | 20,726 | 225K USD |
| 24 Aug 2026 | WILSON TROY EDWARDPresident and CEO | Buy | 100,000 | 1.2M USD |
| 21 Aug 2026 | Powl Brian T.Chief Commercial Officer | Sell | 4,345 | 52K USD |
| 19 Aug 2026 | Bair Teresa BrophyChief Legal Officer | Sell | 31,487 | 398K USD |
| Bought | 2 open-market purchases | 200,000 | $2.35M | |
| Sold | 11 open-market sales | 153,881 | $1.71M |
Showing the 12 most recent of 13 open-market trades in this window. The figures above count all of them.
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 24 Sep 2026 | Burrows FrancisChief Scientific Officer | Option exercise | 30,000 | 185K USD |
Which funds hold Kura Oncology (KURA)?
8 of the 45 institutional funds we track reported a Kura Oncology position for the quarter ended 30 Jun 2026 — a combined 77.9M USD; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| AQR Capital Management | Added | 3,126,727 | 34.3M USD | +47.2% |
| Renaissance Technologies | Held (±25%) | 1,663,765 | 18.3M USD | +5.1% |
| Millennium Management | Trimmed | 711,332 | 7.8M USD | −54.6% |
| Fisher Asset Management | Held (±25%) | 625,936 | 6.9M USD | −7.3% |
| Man Group | Held (±25%) | 432,908 | 4.7M USD | −8.9% |
| Citadel Advisors | Held (±25%) | 328,105 | 3.6M USD | −11.0% |
| Two Sigma Investments | Trimmed | 167,581 | 1.8M USD | −53.2% |
| Tudor Investment Corp | Held (±25%) | 43,520 | 477K USD |
Have members of Congress traded Kura Oncology (KURA)?
The most recent congressional trade disclosed in Kura Oncology is a purchase by Sara Jacobs (house, CA), dated 12 Dec 2022.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 12 Dec 2022 | Sara Jacobshouse · Democrat–CA | Purchase | 1K USD–15K USD | 39 days |
What has been filed or recorded for Kura Oncology (KURA)?
The filings we hold for Kura Oncology, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 08 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 429 shares | 5K USD notional · <0.001% of shares out |
| 17 Sep 2026 | Fails to deliver | Shares failed to deliver | 2,963 shares | 33K USD notional · 0.003% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.77 USD | Revenue $21M |
| 30 Jun 2026 | Financials | Total assets | 587.8M USD | at period end |
| 30 Jun 2026 | Financials | Total equity | 48.4M USD | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.83 USD | Revenue $18M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −3.18 USD | Revenue $67M |
| 31 Dec 2025 | Financials | Revenue | 67.5M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −278.7M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −3.18 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.85 USD | Revenue $21M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.75 USD | Revenue $15M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.66 USD | Revenue $14M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −2.02 USD | Revenue $54M |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −0.63 USD |
Kura Oncology (KURA): frequently asked questions
What did Kura Oncology shares close at?
Kura Oncology closed at 11.00 USD on 23 Sep 2026, down 6.22% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Kura Oncology’s market cap?
Kura Oncology is worth 978.6M USD by market value as of 23 Sep 2026, which is the share price times the shares on issue from its SEC filings.
What is Kura Oncology’s revenue?
Kura Oncology reported revenue of 67.5M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Kura Oncology insiders bought or sold shares recently?
In the 90 days to 1 Nov 2026, Kura Oncology insiders reported 11 open-market sales and 2 purchases (SEC Form 4). A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders
Which funds own Kura Oncology?
8 of the 45 funds we track reported a Kura Oncology position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Renaissance Technologies and Millennium Management. See Funds
Have members of Congress traded Kura Oncology?
Yes. 1 trade in Kura Oncology appears in the congressional disclosures we hold: a purchase by Sara Jacobs (House, CA) dated 12 Dec 2022, filed 20 Jan 2023. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Kura Oncology last report earnings?
Kura Oncology last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.77 USD; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings